# Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

> **NCT01669421** · PHASE2 · COMPLETED · sponsor: **Michael Campos, MD** · enrollment: 10 (actual)

## Conditions studied

- Alpha 1 Antitrypsin Deficiency

## Interventions

- **DRUG:** Alpha-1 Antitrypsin (human)

## Key facts

- **NCT ID:** NCT01669421
- **Lead sponsor:** Michael Campos, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01669421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01669421, "Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01669421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*